1). Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, editors. Fields virology. 5th ed.Philadelphia, PA: Lippincott Williams & Wilkins;2007.
2). Stenberg RM. The human cytomegalovirus major immediate-early gene. Intervirology. 1996; 39:343–9.
Article
3). Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011; 12:695–708.
4). Kowalik TF, Wing B, Haskill JS, Azizkhan JC, Baldwin AS Jr, Huang ES. Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegalovirus infection. Proc Natl Acad Sci U S A. 1993; 90:1107–11.
Article
5). Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 1989; 8:4251–8.
Article
6). Yurochko AD, Huang ES. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J Immunol. 1999; 162:4806–16.
7). Yurochko AD, Hwang ES, Rasmussen L, Keay S, Pereira L, Huang ES. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. J Virol. 1997; 71:5051–9.
Article
8). Yurochko AD, Mayo MW, Poma EE, Baldwin AS Jr, Huang ES. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters. J Virol. 1997; 71:4638–48.
Article
9). Johnson RA, Huong SM, Huang ES. Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for activation of p38. J Virol. 2000; 74:1158–67.
Article
10). Johnson RA, Ma XL, Yurochko AD, Huang ES. The role of MKK1/2 kinase activity in human cytomegalovirus infection. J Gen Virol. 2001; 82:493–7.
Article
11). Yurochko AD, Kowalik TF, Huong SM, Huang ES. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol. 1995; 69:5391–400.
Article
12). Jiang HY, Petrovas C, Sonenshein GE. RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members. J Virol. 2002; 76:5737–47.
13). Wang X, Sonenshein GE. Induction of the RelB NF-kappaB subunit by the cytomegalovirus IE1 protein is mediated via Jun kinase and c-Jun/Fra-2 AP-1 complexes. J Virol. 2005; 79:95–105.
14). Billstrom Schroeder M, Worthen GS. Viral regulation of RANTES expression during human cytomegalovirus infection of endothelial cells. J Virol. 2001; 75:3383–90.
Article
15). Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003; 77:4588–96.
Article
16). Grundy JE, Lawson KM, MacCormac LP, Fletcher JM, Yong KL. Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of C-X-C chemokines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transendothelial migration. J Infect Dis. 1998; 177:1465–74.
Article
17). Hirsch AJ, Shenk T. Human cytomegalovirus inhibits transcription of the CC chemokine MCP-1 gene. J Virol. 1999; 73:404–10.
Article
18). Murayama T, Mukaida N, Sadanari H, Yamaguchi N, Khabar KS, Tanaka J, et al. The immediate early gene 1 product of human cytomegalovirus is sufficient for upregulation of interleukin-8 gene expression. Biochem Biophys Res Commun. 2000; 279:298–304.
Article
19). Poole E, Atkins E, Nakayama T, Yoshie O, Groves I, Alcami A, et al. NF-kappaB-mediated activation of the chemokine CCL22 by the product of the human cytomegalovirus gene UL144 escapes regulation by viral IE86. J Virol. 2008; 82:4250–6.
20). Le VT, Trilling M, Hengel H. The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation of TNF-alpha signaling. J Virol. 2011; 85:13260–70.
21). Goodrum F, Reeves M, Sinclair J, High K, Shenk T. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood. 2007; 110:937–45.
22). Taylor RT, Bresnahan WA. Human cytomegalovirus IE86 attenuates virus- and tumor necrosis factor alpha-induced NFkappaB-dependent gene expression. J Virol. 2006; 80:10763–71.
23). Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci U S A. 2003; 100:11439–44.
Article
24). Abate DA, Watanabe S, Mocarski ES. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol. 2004; 78:10995–1006.
Article
25). Stamminger T, Gstaiger M, Weinzierl K, Lorz K, Winkler M, Schaffner W. Open reading frame UL26 of human cytomegalovirus encodes a novel tegument protein that contains a strong transcriptional activation domain. J Virol. 2002; 76:4836–47.
Article
26). Munger J, Yu D, Shenk T. UL26-deficient human cytomegalovirus produces virions with hypophos-phorylated pp28 tegument protein that is unstable within newly infected cells. J Virol. 2006; 80:3541–8.
Article
27). Mathers C, Schafer X, Martínez-Sobrido L, Munger J. The human cytomegalovirus UL26 protein antagonizes NF-kappaB activation. J Virol. 2014; 88:14289–300.
28). Baillie J, Sahlender DA, Sinclair JH. Human cytomegalovirus infection inhibits tumor necrosis factor alpha (TNF-alpha) signaling by targeting the 55-kilodalton TNF-alpha receptor. J Virol. 2003; 77:7007–16.
29). Jarvis MA, Borton JA, Keech AM, Wong J, Britt WJ, Magun BE, et al. Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha pro-inflammatory signaling by inhibition of NF-kappaB activation. J Virol. 2006; 80:5588–98.
30). Montag C, Wagner J, Gruska I, Hagemeier C. Human cytomegalovirus blocks tumor necrosis factor alpha- and interleukin-1beta-mediated NF-kappaB signaling. J Virol. 2006; 80:11686–98.